{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:20:49Z","timestamp":1789654849044,"version":"4.0.1"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Joint Fund for Innovation and Development of the Shandong Natural Science Foundation","award":["No.ZR2022LSW024"],"award-info":[{"award-number":["No.ZR2022LSW024"]}]},{"name":"the Clinical Medicine +X Project of Qingdao University","award":["No.2020018"],"award-info":[{"award-number":["No.2020018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Platelets not only participate in thrombosis and hemostasis but also interact with tumor cells and protect them from mechanical damage caused by hemodynamic shear stress and natural killer cell lysis, thereby promoting their colonization and metastasis to distant organs. Platelets can affect the tumor microenvironment via interactions between platelet-related factors and tumor cells. Metastasis is a key event in cancer-related death and is associated with platelet-related factors in lung, breast, and colorectal cancers. Although the factors that promote platelet expression vary slightly in terms of their type and mode of action, they all contribute to the overall process. Recognizing the correlation and mechanisms between these factors is crucial for studying the colonization of distant target organs and developing targeted therapies for these three types of tumors. This paper reviews studies on major platelet-related factors closely associated with metastasis in lung, breast, and colorectal cancers.<\/jats:p>","DOI":"10.1186\/s12967-024-05126-6","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T06:20:47Z","timestamp":1713421247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The interaction of platelet-related factors with tumor cells promotes tumor metastasis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jie","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"5","key":"5126_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576\u201390.","journal-title":"Cancer Cell"},{"issue":"3","key":"5126_CR2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1152\/physrev.1983.63.3.1114","volume":"63","author":"AB Malik","year":"1983","unstructured":"Malik AB. Pulmonary microembolism. Physiol Rev. 1983;63(3):1114\u2013207.","journal-title":"Physiol Rev"},{"issue":"1","key":"5126_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","volume":"24","author":"D Schumacher","year":"2013","unstructured":"Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130\u20137.","journal-title":"Cancer Cell"},{"issue":"Suppl 2","key":"5126_CR4","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/S0049-3848(14)50025-4","volume":"133","author":"D Stegner","year":"2014","unstructured":"Stegner D, D\u00fctting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014;133(Suppl 2):S149\u201357.","journal-title":"Thromb Res"},{"issue":"3","key":"5126_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccell.2017.07.001","volume":"32","author":"B Strilic","year":"2017","unstructured":"Strilic B, Offermanns S. Intravascular survival and extravasation of Tumor cells. Cancer Cell. 2017;32(3):282\u201393.","journal-title":"Cancer Cell"},{"issue":"2","key":"5126_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10555-017-9673-1","volume":"36","author":"MZ Wojtukiewicz","year":"2017","unstructured":"Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249\u201362.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"5126_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41467-017-00411-z","volume":"8","author":"M Haemmerle","year":"2017","unstructured":"Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017;8(1):310.","journal-title":"Nat Commun"},{"issue":"3","key":"5126_CR8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.celrep.2018.03.092","volume":"23","author":"Y Ward","year":"2018","unstructured":"Ward Y, Lake R, Faraji F, Sperger J, Martin P, Gilliard C, et al. Platelets promote metastasis via binding tumor CD97 leading to bidirectional signaling that coordinates Transendothelial Migration. Cell Rep. 2018;23(3):808\u201322.","journal-title":"Cell Rep"},{"issue":"20","key":"5126_CR9","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1182\/blood-2014-04-568683","volume":"124","author":"R Leblanc","year":"2014","unstructured":"Leblanc R, Lee SC, David M, Bordet JC, Norman DD, Patil R, et al. Interaction of platelet-derived autotaxin with tumor integrin \u03b1V\u03b23 controls metastasis of breast cancer cells to bone. Blood. 2014;124(20):3141\u201350.","journal-title":"Blood"},{"issue":"4","key":"5126_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1083\/jcb.124.4.619","volume":"124","author":"SM Frisch","year":"1994","unstructured":"Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124(4):619\u201326.","journal-title":"J Cell Biol"},{"issue":"2","key":"5126_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.029","volume":"272","author":"CD Simpson","year":"2008","unstructured":"Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177\u201385.","journal-title":"Cancer Lett"},{"issue":"5","key":"5126_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/A:1016377114119","volume":"19","author":"B Felding-Habermann","year":"2002","unstructured":"Felding-Habermann B, Fransvea E, O\u2019Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis. 2002;19(5):427\u201336.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"5126_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF00114587","volume":"10","author":"KR Gehlsen","year":"1992","unstructured":"Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis. 1992;10(2):111\u201320.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"5126_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nrc1276","volume":"4","author":"U Cavallaro","year":"2004","unstructured":"Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118\u201332.","journal-title":"Nat Rev Cancer"},{"key":"5126_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/B978-0-12-394311-8.00014-5","volume":"116","author":"A Gheldof","year":"2013","unstructured":"Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 2013;116:317\u201336.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"11","key":"5126_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1089\/ars.2011.4280","volume":"16","author":"E Giannoni","year":"2012","unstructured":"Giannoni E, Parri M, Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal. 2012;16(11):1248\u201363.","journal-title":"Antioxid Redox Signal"},{"key":"5126_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1476-4598-6-61","volume":"6","author":"JP Cosse","year":"2007","unstructured":"Cosse JP, Sermeus A, Vannuvel K, Ninane N, Raes M, Michiels C. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer. 2007;6:61.","journal-title":"Mol Cancer"},{"key":"5126_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1476-4598-7-27","volume":"7","author":"A Sermeus","year":"2008","unstructured":"Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, Ninane N, et al. Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer. 2008;7:27.","journal-title":"Mol Cancer"},{"issue":"12","key":"5126_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/BF01209121","volume":"122","author":"E Heinm\u00f6ller","year":"1996","unstructured":"Heinm\u00f6ller E, Weinel RJ, Heidtmann HH, Salge U, Seitz R, Schmitz I, et al. Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol. 1996;122(12):735\u201344.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"5126_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12282-012-0334-5","volume":"20","author":"K Asanuma","year":"2013","unstructured":"Asanuma K, Wakabayashi H, Okamoto T, Asanuma Y, Akita N, Yoshikawa T, et al. The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. Breast Cancer. 2013;20(3):241\u20136.","journal-title":"Breast Cancer"},{"issue":"Suppl 1","key":"5126_CR21","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.thromres.2018.01.035","volume":"164","author":"L Plantureux","year":"2018","unstructured":"Plantureux L, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C. Effects of platelets on cancer progression. Thromb Res. 2018;164(Suppl 1):S40\u20137.","journal-title":"Thromb Res"},{"issue":"1","key":"5126_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5126_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0952-3278(02)00235-1","volume":"68","author":"X de Leval","year":"2003","unstructured":"de Leval X, Benoit V, Delarge J, Jul\u00e9mont F, Masereel B, Pirotte B, et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II\/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot Essent Fat Acids. 2003;68(1):55\u20139.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"issue":"19","key":"5126_CR24","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1158\/0008-5472.CAN-15-0964","volume":"75","author":"GN Adams","year":"2015","unstructured":"Adams GN, Rosenfeldt L, Frederick M, Miller W, Waltz D, Kombrinck K, et al. Colon Cancer Growth and Dissemination relies upon Thrombin, stromal PAR-1, and Fibrinogen. Cancer Res. 2015;75(19):4235\u201343.","journal-title":"Cancer Res"},{"issue":"1","key":"5126_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-2002-20564","volume":"28","author":"NM Varki","year":"2002","unstructured":"Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost. 2002;28(1):53\u201366.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"5126_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.7326\/0003-4819-95-5-636","volume":"95","author":"S Karpatkin","year":"1981","unstructured":"Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981;95(5):636\u201341.","journal-title":"Ann Intern Med"},{"issue":"6024","key":"5126_CR27","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559\u201364.","journal-title":"Science"},{"issue":"1","key":"5126_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5126_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5126_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CCO.0000000000000703","volume":"33","author":"F Wu","year":"2021","unstructured":"Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect. Curr Opin Oncol. 2021;33(1):40\u20136.","journal-title":"Curr Opin Oncol"},{"key":"5126_CR31","doi-asserted-by":"publisher","first-page":"112963","DOI":"10.1016\/j.biopha.2022.112963","volume":"150","author":"M Entezari","year":"2022","unstructured":"Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi M, et al. Long non-coding RNAs and exosomal lncRNAs: potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomed Pharmacother. 2022;150:112963.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"5126_CR32","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1039\/D0AN02193H","volume":"146","author":"Z Gao","year":"2021","unstructured":"Gao Z, Yuan H, Mao Y, Ding L, Effah CY, He S, et al. In situ detection of plasma exosomal microRNA for lung cancer diagnosis using duplex-specific nuclease and MoS(2) nanosheets. Analyst. 2021;146(6):1924\u201331.","journal-title":"Analyst"},{"key":"5126_CR33","doi-asserted-by":"crossref","unstructured":"Abadi AJ, Zarrabi A, Gholami MH, Mirzaei S, Hashemi F, Zabolian A et al. Small in size, but large in action: microRNAs as potential modulators of PTEN in breast and lung cancers. Biomolecules. 2021;11(2).","DOI":"10.3390\/biom11020304"},{"issue":"12","key":"5126_CR34","doi-asserted-by":"publisher","first-page":"9241","DOI":"10.1002\/jcp.29819","volume":"235","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Najafi M, Makvandi P, Zarrabi A, Farkhondeh T, Samarghandian S. Versatile role of curcumin and its derivatives in lung cancer therapy. J Cell Physiol. 2020;235(12):9241\u201368.","journal-title":"J Cell Physiol"},{"key":"5126_CR35","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.2147\/DDDT.S260253","volume":"14","author":"Y Jin","year":"2020","unstructured":"Jin Y, Wang Y, Liu X, Zhou J, Wang X, Feng H, et al. Synergistic combination chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, glutathione and pH sensitive nanocarriers. Drug Des Devel Ther. 2020;14:5205\u201315.","journal-title":"Drug Des Devel Ther"},{"key":"5126_CR36","doi-asserted-by":"publisher","first-page":"109871","DOI":"10.1016\/j.cellsig.2020.109871","volume":"78","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Moghadam ER, Owrang M, et al. Lung cancer cells and their sensitivity\/resistance to cisplatin chemotherapy: role of microRNAs and upstream mediators. Cell Signal. 2021;78:109871.","journal-title":"Cell Signal"},{"key":"5126_CR37","doi-asserted-by":"publisher","first-page":"119649","DOI":"10.1016\/j.lfs.2021.119649","volume":"278","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh M, Mirzaei S, Hushmandi K, Rahmanian V, Zabolian A, Raei M, et al. Therapeutic potential of AMPK signaling targeting in lung cancer: advances, challenges and future prospects. Life Sci. 2021;278:119649.","journal-title":"Life Sci"},{"issue":"1","key":"5126_CR38","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","volume":"12","author":"C Hinterleitner","year":"2021","unstructured":"Hinterleitner C, Str\u00e4hle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021;12(1):7005.","journal-title":"Nat Commun"},{"issue":"18","key":"5126_CR39","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378.","journal-title":"N Engl J Med"},{"issue":"4","key":"5126_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"5126_CR41","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"issue":"20","key":"5126_CR42","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1182\/bloodadvances.2021006120","volume":"6","author":"Q Guo","year":"2022","unstructured":"Guo Q, Malloy MW, Roweth HG, McAllister SS, Italiano JE, Battinelli EM. Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro. Blood Adv. 2022;6(20):5668\u201375.","journal-title":"Blood Adv"},{"issue":"3","key":"5126_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","volume":"71","author":"A Kythreotou","year":"2018","unstructured":"Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol. 2018;71(3):189\u201394.","journal-title":"J Clin Pathol"},{"issue":"3\u20134","key":"5126_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0165-2427(03)00163-6","volume":"96","author":"A Massaguer","year":"2003","unstructured":"Massaguer A, Engel P, Tovar V, March S, Rigol M, Solanes N, et al. Characterization of platelet and soluble-porcine P-selectin (CD62P). Vet Immunol Immunopathol. 2003;96(3\u20134):169\u201381.","journal-title":"Vet Immunol Immunopathol"},{"issue":"8","key":"5126_CR45","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1517\/14728222.11.8.1103","volume":"11","author":"RJ Ludwig","year":"2007","unstructured":"Ludwig RJ, Sch\u00f6n MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets. 2007;11(8):1103\u201317.","journal-title":"Expert Opin Ther Targets"},{"key":"5126_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev.immunol.21.090501.080131","volume":"22","author":"SD Rosen","year":"2004","unstructured":"Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004;22:129\u201356.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"5126_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1600-065X.2009.00795.x","volume":"230","author":"M Sperandio","year":"2009","unstructured":"Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking. Immunol Rev. 2009;230(1):97\u2013113.","journal-title":"Immunol Rev"},{"issue":"9","key":"5126_CR48","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1182\/blood.V88.9.3259.bloodjournal8893259","volume":"88","author":"GS Kansas","year":"1996","unstructured":"Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88(9):3259\u201387.","journal-title":"Blood"},{"issue":"2","key":"5126_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00005-006-0010-6","volume":"54","author":"M Chen","year":"2006","unstructured":"Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz). 2006;54(2):75\u201384.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"4","key":"5126_CR50","doi-asserted-by":"publisher","first-page":"e92327","DOI":"10.1371\/journal.pone.0092327","volume":"9","author":"F Heidemann","year":"2014","unstructured":"Heidemann F, Schildt A, Schmid K, Bruns OT, Riecken K, Jung C, et al. Selectins mediate small cell lung cancer systemic metastasis. PLoS ONE. 2014;9(4):e92327.","journal-title":"PLoS ONE"},{"issue":"4","key":"5126_CR51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s12253-012-9531-y","volume":"18","author":"L Gong","year":"2012","unstructured":"Gong L, Cai Y, Zhou X, Yang H. Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. Pathol Oncol Res. 2012;18(4):989\u201396.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"5126_CR52","doi-asserted-by":"publisher","first-page":"541","DOI":"10.21873\/anticanres.13146","volume":"39","author":"N Aksorn","year":"2019","unstructured":"Aksorn N, Chanvorachote P. Integrin as a molecular target for anti-cancer approaches in Lung Cancer. Anticancer Res. 2019;39(2):541\u20138.","journal-title":"Anticancer Res"},{"issue":"12","key":"5126_CR53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrm2799","volume":"10","author":"PT Caswell","year":"2009","unstructured":"Caswell PT, Vadrevu S, Norman JC. Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol. 2009;10(12):843\u201353.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"5126_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"5126_CR55","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1083\/jcb.108.5.1917","volume":"108","author":"WD Staatz","year":"1989","unstructured":"Staatz WD, Rajpara SM, Wayner EA, Carter WG, Santoro SA. The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mg++-dependent adhesion of platelets to collagen. J Cell Biol. 1989;108(5):1917\u201324.","journal-title":"J Cell Biol"},{"issue":"6","key":"5126_CR56","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1083\/jcb.99.6.2140","volume":"99","author":"CR Ill","year":"1984","unstructured":"Ill CR, Engvall E, Ruoslahti E. Adhesion of platelets to laminin in the absence of activation. J Cell Biol. 1984;99(6):2140\u20135.","journal-title":"J Cell Biol"},{"issue":"6198","key":"5126_CR57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/336487a0","volume":"336","author":"A Sonnenberg","year":"1988","unstructured":"Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. Nature. 1988;336(6198):487\u20139.","journal-title":"Nature"},{"issue":"9","key":"5126_CR58","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18(9):533\u201348.","journal-title":"Nat Rev Cancer"},{"key":"5126_CR59","doi-asserted-by":"crossref","unstructured":"Lavergne M, Janus-Bell E, Schaff M, Gachet C, Mangin PH. Platelet integrins in Tumor Metastasis: do they represent a therapeutic target? Cancers (Basel). 2017;9(10).","DOI":"10.3390\/cancers9100133"},{"issue":"3","key":"5126_CR60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/ATVBAHA.107.150474","volume":"28","author":"D Varga-Szabo","year":"2008","unstructured":"Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):403\u201312.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"5126_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-019-0709-6","volume":"12","author":"J Huang","year":"2019","unstructured":"Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, et al. Platelet integrin \u03b1IIb\u03b23: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12(1):26.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"5126_CR62","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1096\/fasebj.2.8.2452113","volume":"2","author":"IM Grossi","year":"1988","unstructured":"Grossi IM, Hatfield JS, Fitzgerald LA, Newcombe M, Taylor JD, Honn KV. Role of tumor cell glycoproteins immunologically related to glycoproteins ib and IIb\/IIIa in tumor cell-platelet and tumor cell-matrix interactions. Faseb j. 1988;2(8):2385\u201395.","journal-title":"Faseb j"},{"issue":"1","key":"5126_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0014-4827(92)90344-8","volume":"201","author":"KV Honn","year":"1992","unstructured":"Honn KV, Chen YQ, Timar J, Onoda JM, Hatfield JS, Fligiel SE, et al. Alpha IIb beta 3 integrin expression and function in subpopulations of murine tumors. Exp Cell Res. 1992;201(1):23\u201332.","journal-title":"Exp Cell Res"},{"issue":"5","key":"5126_CR64","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1023\/A:1006533508560","volume":"16","author":"J Timar","year":"1998","unstructured":"Timar J, Trikha M, Szekeres K, Bazaz R, Honn K. Expression and function of the high affinity alphaIIbbeta3 integrin in murine melanoma cells. Clin Exp Metastasis. 1998;16(5):437\u201345.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"5126_CR65","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1182\/blood.V74.2.658.658","volume":"74","author":"H Boukerche","year":"1989","unstructured":"Boukerche H, Berthier-Vergnes O, Tabone E, Dor\u00e9 JF, Leung LL, McGregor JL. Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. Blood. 1989;74(2):658\u201363.","journal-title":"Blood"},{"issue":"3","key":"5126_CR66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","volume":"35","author":"J Cooper","year":"2019","unstructured":"Cooper J, Giancotti FG. Integrin signaling in Cancer: mechanotransduction, stemness, epithelial plasticity, and Therapeutic Resistance. Cancer Cell. 2019;35(3):347\u201367.","journal-title":"Cancer Cell"},{"issue":"5","key":"5126_CR67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ncb2953","volume":"16","author":"L Seguin","year":"2014","unstructured":"Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, et al. An integrin \u03b23-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014;16(5):457\u201368.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"5126_CR68","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","volume":"25","author":"L Seguin","year":"2015","unstructured":"Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25(4):234\u201340.","journal-title":"Trends Cell Biol"},{"issue":"10","key":"5126_CR69","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.2009","volume":"15","author":"JS Desgrosellier","year":"2009","unstructured":"Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Pr\u00e9vost N, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009;15(10):1163\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"5126_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.critrevonc.2015.05.018","volume":"96","author":"S Stucci","year":"2015","unstructured":"Stucci S, Tucci M, Passarelli A, Silvestris F. Av\u03b23 integrin: Pathogenetic role in osteotropic tumors. Crit Rev Oncol Hematol. 2015;96(1):183\u201393.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5158","key":"5126_CR71","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.7512751","volume":"264","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264(5158):569\u201371.","journal-title":"Science"},{"issue":"Pt 7","key":"5126_CR72","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1242\/jcs.108.7.2655","volume":"108","author":"CJ Drake","year":"1995","unstructured":"Drake CJ, Cheresh DA, Little CD. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci. 1995;108(Pt 7):2655\u201361.","journal-title":"J Cell Sci"},{"issue":"20","key":"5126_CR73","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/0008-5472.CAN-13-0602","volume":"73","author":"LM Knowles","year":"2013","unstructured":"Knowles LM, Gurski LA, Engel C, Gnarra JR, Maranchie JK, Pilch J. Integrin \u03b1v\u03b23 and fibronectin upregulate slug in cancer cells to promote clot invasion and metastasis. Cancer Res. 2013;73(20):6175\u201384.","journal-title":"Cancer Res"},{"issue":"11","key":"5126_CR74","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1158\/0008-5472.CAN-09-3312","volume":"70","author":"G Malik","year":"2010","unstructured":"Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res. 2010;70(11):4327\u201334.","journal-title":"Cancer Res"},{"issue":"8","key":"5126_CR75","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc1143","volume":"3","author":"GB Mills","year":"2003","unstructured":"Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3(8):582\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"5126_CR76","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1074\/jbc.M807820200","volume":"284","author":"Z Pamuklar","year":"2009","unstructured":"Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, Panchatcharam M, et al. Autotaxin\/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem. 2009;284(11):7385\u201394.","journal-title":"J Biol Chem"},{"issue":"13","key":"5126_CR77","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1158\/0008-5472.CAN-17-3797","volume":"78","author":"C Magkrioti","year":"2018","unstructured":"Magkrioti C, Oikonomou N, Kaffe E, Mouratis MA, Xylourgidis N, Barbayianni I, et al. The Autotaxin-Lysophosphatidic Acid Axis promotes Lung Carcinogenesis. Cancer Res. 2018;78(13):3634\u201344.","journal-title":"Cancer Res"},{"issue":"2","key":"5126_CR78","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1165\/ajrcmb.21.2.3667","volume":"21","author":"Y Yang","year":"1999","unstructured":"Yang Y, Mou L, Liu N, Tsao MS. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol. 1999;21(2):216\u201322.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"5126_CR79","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27\u201331.","journal-title":"Nat Med"},{"issue":"5","key":"5126_CR80","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2796.2003.01297.x","volume":"255","author":"P Carmeliet","year":"2004","unstructured":"Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med. 2004;255(5):538\u201361.","journal-title":"J Intern Med"},{"issue":"30","key":"5126_CR81","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.2174\/092986707782793907","volume":"14","author":"H Kuhn","year":"2007","unstructured":"Kuhn H, Hammerschmidt S, Wirtz H. Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor - results from clinical trials and novel experimental approaches. Curr Med Chem. 2007;14(30):3157\u201365.","journal-title":"Curr Med Chem"},{"issue":"8","key":"5126_CR82","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1046\/j.1538-7836.2003.00344.x","volume":"1","author":"J Folkman","year":"2003","unstructured":"Folkman J. Angiogenesis and proteins of the hemostatic system. J Thromb Haemost. 2003;1(8):1681\u20132.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"5126_CR83","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/74651","volume":"6","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389\u201395.","journal-title":"Nat Med"},{"issue":"10","key":"5126_CR84","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s11255-019-02190-6","volume":"51","author":"E Cecerska-Hery\u0107","year":"2019","unstructured":"Cecerska-Hery\u0107 E, Hery\u0107 R, Wi\u015bniewska M, Michalczyk A, Do\u0142\u0119gowska B. Regenerative potential of platelets in patients with chronic kidney disease. Int Urol Nephrol. 2019;51(10):1831\u201340.","journal-title":"Int Urol Nephrol"},{"issue":"5\u20136","key":"5126_CR85","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.vph.2012.01.002","volume":"56","author":"Y Sato","year":"2012","unstructured":"Sato Y. The vasohibin family: novel regulators of angiogenesis. Vascul Pharmacol. 2012;56(5\u20136):262\u20136.","journal-title":"Vascul Pharmacol"},{"issue":"3","key":"5126_CR86","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.gde.2009.04.002","volume":"19","author":"S Wang","year":"2009","unstructured":"Wang S, Olson EN. AngiomiRs\u2013key regulators of angiogenesis. Curr Opin Genet Dev. 2009;19(3):205\u201311.","journal-title":"Curr Opin Genet Dev"},{"issue":"6","key":"5126_CR87","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669\u201376.","journal-title":"Nat Med"},{"issue":"12","key":"5126_CR88","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","volume":"5","author":"KA Houck","year":"1991","unstructured":"Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991;5(12):1806\u201314.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"5126_CR89","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1074\/jbc.M411395200","volume":"280","author":"K Suto","year":"2005","unstructured":"Suto K, Yamazaki Y, Morita T, Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem. 2005;280(3):2126\u201331.","journal-title":"J Biol Chem"},{"issue":"21","key":"5126_CR90","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF. Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368\u201380.","journal-title":"J Clin Oncol"},{"key":"5126_CR91","doi-asserted-by":"crossref","unstructured":"Karaman S, Paavonsalo S, Heinolainen K, Lackman MH, Ranta A, Hemanthakumar KA et al. Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance. J Exp Med. 2022;219(3).","DOI":"10.1084\/jem.20210565"},{"issue":"12","key":"5126_CR92","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/01.RES.86.12.1198","volume":"86","author":"C Kalka","year":"2000","unstructured":"Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 2000;86(12):1198\u2013202.","journal-title":"Circ Res"},{"issue":"1","key":"5126_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0177(2000)9999:9999<::AID-DVDY1087>3.0.CO;2-2","volume":"220","author":"TJ Poole","year":"2001","unstructured":"Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn. 2001;220(1):1\u201317.","journal-title":"Dev Dyn"},{"issue":"2","key":"5126_CR94","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1242\/dev.116.2.435","volume":"116","author":"I Flamme","year":"1992","unstructured":"Flamme I, Risau W. Induction of vasculogenesis and hematopoiesis in vitro. Development. 1992;116(2):435\u20139.","journal-title":"Development"},{"issue":"2\u20133","key":"5126_CR95","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000063781","volume":"12","author":"S Kazemi","year":"2002","unstructured":"Kazemi S, Wenzel D, Kolossov E, Lenka N, Raible A, Sasse P, et al. Differential role of bFGF and VEGF for vasculogenesis. Cell Physiol Biochem. 2002;12(2\u20133):55\u201362.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"5126_CR96","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I","volume":"74","author":"M Volm","year":"1997","unstructured":"Volm M, Koom\u00e4gi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 1997;74(1):64\u20138.","journal-title":"Int J Cancer"},{"issue":"1","key":"5126_CR97","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.lungcan.2004.03.006","volume":"46","author":"S Tanno","year":"2004","unstructured":"Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer. 2004;46(1):11\u20139.","journal-title":"Lung Cancer"},{"issue":"1","key":"5126_CR98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10555-016-9618-0","volume":"35","author":"HH Popper","year":"2016","unstructured":"Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35(1):75\u201391.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"5126_CR99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bcpt.13290","volume":"126","author":"Z Wang","year":"2020","unstructured":"Wang Z, Xu H, Zhang J, Jin H, Wei P. Basic fibroblast growth factor blockade enhances lung cancer cell invasion by activating the AKT\/MMP-2\/VEGF pathway. Basic Clin Pharmacol Toxicol. 2020;126(1):43\u201350.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"5126_CR100","doi-asserted-by":"publisher","first-page":"e0147374","DOI":"10.1371\/journal.pone.0147374","volume":"11","author":"M Hu","year":"2016","unstructured":"Hu M, Hu Y, He J, Li B. Prognostic Value of Basic Fibroblast Growth factor (bFGF) in Lung Cancer: a systematic review with Meta-analysis. PLoS ONE. 2016;11(1):e0147374.","journal-title":"PLoS ONE"},{"issue":"1","key":"5126_CR101","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"10125","key":"5126_CR102","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375.","journal-title":"Lancet"},{"issue":"7418","key":"5126_CR103","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular portraits","year":"2012","unstructured":"Comprehensive molecular portraits. Of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"4","key":"5126_CR104","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1073\/pnas.98.4.1853","volume":"98","author":"B Felding-Habermann","year":"2001","unstructured":"Felding-Habermann B, O\u2019Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A. 2001;98(4):1853\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"5126_CR105","doi-asserted-by":"publisher","first-page":"e0260124","DOI":"10.1371\/journal.pone.0260124","volume":"16","author":"EP Darga","year":"2021","unstructured":"Darga EP, Dolce EM, Fang F, Kidwell KM, Gersch CL, Kregel S, et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS ONE. 2021;16(11):e0260124.","journal-title":"PLoS ONE"},{"issue":"1","key":"5126_CR106","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"5126_CR107","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in Non-small Cell Lung Cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592\u2013602.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5126_CR108","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1160\/TH04-05-0306","volume":"92","author":"ER Vandendries","year":"2004","unstructured":"Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004;92(3):459\u201366.","journal-title":"Thromb Haemost"},{"key":"5126_CR109","doi-asserted-by":"crossref","unstructured":"Schwarz S, Gockel LM, Naggi A, Barash U, Gobec M, Bendas G et al. Glycosaminoglycans as tools to decipher the platelet Tumor Cell Interaction: a focus on P-Selectin. Molecules. 2020;25(5).","DOI":"10.3390\/molecules25051039"},{"issue":"6","key":"5126_CR110","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1073\/pnas.061615598","volume":"98","author":"L Borsig","year":"2001","unstructured":"Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98(6):3352\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5126_CR111","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2008-05-155978","volume":"113","author":"P Flevaris","year":"2009","unstructured":"Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood. 2009;113(4):893\u2013901.","journal-title":"Blood"},{"issue":"45","key":"5126_CR112","doi-asserted-by":"publisher","first-page":"42226","DOI":"10.1074\/jbc.M106129200","volume":"276","author":"Z Li","year":"2001","unstructured":"Li Z, Xi X, Du X. A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIbbeta3. J Biol Chem. 2001;276(45):42226\u201332.","journal-title":"J Biol Chem"},{"issue":"2","key":"5126_CR113","first-page":"162","volume":"32","author":"B Estevez","year":"2017","unstructured":"Estevez B, Du X. New concepts and mechanisms of platelet activation signaling. Physiol (Bethesda). 2017;32(2):162\u201377.","journal-title":"Physiol (Bethesda)"},{"issue":"9","key":"5126_CR114","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.18632\/oncotarget.3164","volume":"6","author":"C Qi","year":"2015","unstructured":"Qi C, Wei B, Zhou W, Yang Y, Li B, Guo S, et al. P-selectin-mediated platelet adhesion promotes tumor growth. Oncotarget. 2015;6(9):6584\u201396.","journal-title":"Oncotarget"},{"key":"5126_CR115","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1749-6632.2000.tb06549.x","volume":"905","author":"EJ Goetzl","year":"2000","unstructured":"Goetzl EJ, Lee H, Dolezalova H, Kalli KR, Conover CA, Hu YL, et al. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann N Y Acad Sci. 2000;905:177\u201387.","journal-title":"Ann N Y Acad Sci"},{"issue":"39","key":"5126_CR116","doi-asserted-by":"publisher","first-page":"27776","DOI":"10.1074\/jbc.274.39.27776","volume":"274","author":"K Bandoh","year":"1999","unstructured":"Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999;274(39):27776\u201385.","journal-title":"J Biol Chem"},{"issue":"28","key":"5126_CR117","doi-asserted-by":"publisher","first-page":"25600","DOI":"10.1074\/jbc.M302648200","volume":"278","author":"K Noguchi","year":"2003","unstructured":"Noguchi K, Ishii S, Shimizu T. Identification of p2y9\/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem. 2003;278(28):25600\u20136.","journal-title":"J Biol Chem"},{"issue":"1","key":"5126_CR118","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1073\/pnas.0135855100","volume":"100","author":"TM McIntyre","year":"2003","unstructured":"McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A. 2003;100(1):131\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"5126_CR119","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1111\/bph.14362","volume":"175","author":"R Leblanc","year":"2018","unstructured":"Leblanc R, Houssin A, Peyruchaud O. Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis. Br J Pharmacol. 2018;175(15):3100\u201310.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"5126_CR120","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1172\/JCI0217124","volume":"110","author":"TJ Martin","year":"2002","unstructured":"Martin TJ. Manipulating the environment of cancer cells in bone: a novel therapeutic approach. J Clin Invest. 2002;110(10):1399\u2013401.","journal-title":"J Clin Invest"},{"issue":"6","key":"5126_CR121","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1172\/JCI117990","volume":"95","author":"J de la Mata","year":"1995","unstructured":"de la Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest. 1995;95(6):2846\u201352.","journal-title":"J Clin Invest"},{"issue":"12","key":"5126_CR122","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1172\/JCI200422123","volume":"114","author":"A Boucharaba","year":"2004","unstructured":"Boucharaba A, Serre CM, Gr\u00e8s S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114(12):1714\u201325.","journal-title":"J Clin Invest"},{"issue":"14","key":"5126_CR123","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/onc.2011.365","volume":"31","author":"H Zhang","year":"2012","unstructured":"Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012;31(14):1757\u201370.","journal-title":"Oncogene"},{"issue":"16","key":"5126_CR124","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.1633689100","volume":"100","author":"M Rolli","year":"2003","unstructured":"Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(16):9482\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5126_CR125","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10555-005-5134-3","volume":"24","author":"PJ Reddig","year":"2005","unstructured":"Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005;24(3):425\u201339.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"5126_CR126","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.200106070","volume":"155","author":"DG Stupack","year":"2001","unstructured":"Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155(3):459\u201370.","journal-title":"J Cell Biol"},{"issue":"10","key":"5126_CR127","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrc905","volume":"2","author":"R Kerbel","year":"2002","unstructured":"Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"2 Suppl","key":"5126_CR128","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/107327480200902S05","volume":"9","author":"LS Rosen","year":"2002","unstructured":"Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002;9(2 Suppl):36\u201344.","journal-title":"Cancer Control"},{"issue":"6","key":"5126_CR129","doi-asserted-by":"publisher","first-page":"e65217","DOI":"10.1371\/journal.pone.0065217","volume":"8","author":"Q Ning","year":"2013","unstructured":"Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo M, et al. Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition. PLoS ONE. 2013;8(6):e65217.","journal-title":"PLoS ONE"},{"issue":"3","key":"5126_CR130","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF00046362","volume":"9","author":"PA D\u2019Amore","year":"1990","unstructured":"D\u2019Amore PA. Modes of FGF release in vivo and in vitro. Cancer Metastasis Rev. 1990;9(3):227\u201338.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"5126_CR131","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.1997.5","volume":"75","author":"C Yiangou","year":"1997","unstructured":"Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, et al. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer. 1997;75(1):28\u201333.","journal-title":"Br J Cancer"},{"issue":"1","key":"5126_CR132","doi-asserted-by":"publisher","first-page":"17924","DOI":"10.1038\/s41598-018-36394-0","volume":"8","author":"M Farzaneh Behelgardi","year":"2018","unstructured":"Farzaneh Behelgardi M, Zahri S, Mashayekhi F, Mansouri K, Asghari SM. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1\/-2 driven angiogenesis, tumor growth and metastasis. Sci Rep. 2018;8(1):17924.","journal-title":"Sci Rep"},{"issue":"3","key":"5126_CR133","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s11033-020-05306-9","volume":"47","author":"M Farzaneh Behelgardi","year":"2020","unstructured":"Farzaneh Behelgardi M, Zahri S, Gholami Shahvir Z, Mashayekhi F, Mirzanejad L, Asghari SM. Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer. Mol Biol Rep. 2020;47(3):2061\u201371.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"5126_CR134","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1042\/BCJ20180823","volume":"476","author":"E Assareh","year":"2019","unstructured":"Assareh E, Mehrnejad F, Mansouri K, Esmaeili Rastaghi AR, Naderi-Manesh H, Asghari SM. A cyclic peptide reproducing the \u03b11 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth. Biochem J. 2019;476(4):645\u201363.","journal-title":"Biochem J"},{"issue":"5\u20136","key":"5126_CR135","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/10799893.2019.1567785","volume":"38","author":"A Sadremomtaz","year":"2018","unstructured":"Sadremomtaz A, Kobarfard F, Mansouri K, Mirzanejad L, Asghari SM. Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2. J Recept Signal Transduct Res. 2018;38(5\u20136):432\u201341.","journal-title":"J Recept Signal Transduct Res"},{"issue":"12","key":"5126_CR136","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1016\/j.bbagen.2018.08.013","volume":"1862","author":"A Sadremomtaz","year":"2018","unstructured":"Sadremomtaz A, Mansouri K, Alemzadeh G, Safa M, Rastaghi AE, Asghari SM. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K\/AKT and MAPK\/ERK1\/2 pathway. Biochim Biophys Acta Gen Subj. 2018;1862(12):2688\u2013700.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"1","key":"5126_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1078\/0344-0338-00176","volume":"198","author":"A Faridi","year":"2002","unstructured":"Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schr\u00f6der W. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract. 2002;198(1):1\u20135.","journal-title":"Pathol Res Pract"},{"issue":"5 Suppl 16","key":"5126_CR138","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","volume":"30","author":"MA Cobleigh","year":"2003","unstructured":"Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30(5 Suppl 16):117\u201324.","journal-title":"Semin Oncol"},{"issue":"7","key":"5126_CR139","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1046\/j.1365-2168.2002.02120.x","volume":"89","author":"A Leslie","year":"2002","unstructured":"Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002;89(7):845\u201360.","journal-title":"Br J Surg"},{"issue":"9","key":"5126_CR140","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00384-009-0701-7","volume":"24","author":"MH Chew","year":"2009","unstructured":"Chew MH, Koh PK, Ng KH, Eu KW. Improved survival in an Asian cohort of young colorectal cancer patients: an analysis of 523 patients from a single institution. Int J Colorectal Dis. 2009;24(9):1075\u201383.","journal-title":"Int J Colorectal Dis"},{"issue":"10","key":"5126_CR141","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/000313480306901010","volume":"69","author":"JB O\u2019Connell","year":"2003","unstructured":"O\u2019Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69(10):866\u201372.","journal-title":"Am Surg"},{"key":"5126_CR142","doi-asserted-by":"publisher","first-page":"4708076","DOI":"10.1155\/2017\/4708076","volume":"2017","author":"RM Manzat Saplacan","year":"2017","unstructured":"Manzat Saplacan RM, Balacescu L, Gherman C, Chira RI, Craiu A, Mircea PA, et al. The role of PDGFs and PDGFRs in Colorectal Cancer. Mediators Inflamm. 2017;2017:4708076.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"5126_CR143","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283\u2013316.","journal-title":"Physiol Rev"},{"issue":"10","key":"5126_CR144","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276\u2013312.","journal-title":"Genes Dev"},{"issue":"8","key":"5126_CR145","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2013.05.002","volume":"19","author":"Y Cao","year":"2013","unstructured":"Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 2013;19(8):460\u201373.","journal-title":"Trends Mol Med"},{"issue":"19","key":"5126_CR146","doi-asserted-by":"publisher","first-page":"12676","DOI":"10.1074\/jbc.272.19.12676","volume":"272","author":"T Omura","year":"1997","unstructured":"Omura T, Heldin CH, Ostman A. Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. J Biol Chem. 1997;272(19):12676\u201382.","journal-title":"J Biol Chem"},{"issue":"8","key":"5126_CR147","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1007\/s13277-016-5069-z","volume":"37","author":"K Appiah-Kubi","year":"2016","unstructured":"Appiah-Kubi K, Wang Y, Qian H, Wu M, Yao X, Wu Y, et al. Platelet-derived growth factor receptor\/platelet-derived growth factor (PDGFR\/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers. Tumour Biol. 2016;37(8):10053\u201366.","journal-title":"Tumour Biol"},{"issue":"12","key":"5126_CR148","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1096\/fj.02-0319com","volume":"16","author":"R Cao","year":"2002","unstructured":"Cao R, Br\u00e5kenhielm E, Li X, Pietras K, Widenfalk J, Ostman A, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. Faseb j. 2002;16(12):1575\u201383.","journal-title":"Faseb j"},{"issue":"2","key":"5126_CR149","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"5126_CR150","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/2159-8290.CD-12-0329","volume":"2","author":"M Labelle","year":"2012","unstructured":"Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012;2(12):1091\u20139.","journal-title":"Cancer Discov"},{"issue":"5","key":"5126_CR151","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood-2015-02-629717","volume":"126","author":"E Mammadova-Bach","year":"2015","unstructured":"Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood. 2015;126(5):683\u201391.","journal-title":"Blood"},{"issue":"2","key":"5126_CR152","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2002-12-3882","volume":"102","author":"B Nieswandt","year":"2003","unstructured":"Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102(2):449\u201361.","journal-title":"Blood"},{"issue":"41","key":"5126_CR153","doi-asserted-by":"publisher","first-page":"29019","DOI":"10.1074\/jbc.274.41.29019","volume":"274","author":"JM Clemetson","year":"1999","unstructured":"Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem. 1999;274(41):29019\u201324.","journal-title":"J Biol Chem"},{"issue":"4","key":"5126_CR154","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.thromres.2004.06.046","volume":"114","author":"M Moroi","year":"2004","unstructured":"Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res. 2004;114(4):221\u201333.","journal-title":"Thromb Res"},{"issue":"1","key":"5126_CR155","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI122955","volume":"129","author":"J Rayes","year":"2019","unstructured":"Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019;129(1):12\u201323.","journal-title":"J Clin Invest"},{"issue":"1","key":"5126_CR156","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1124\/mol.113.084988","volume":"84","author":"M Dovizio","year":"2013","unstructured":"Dovizio M, Maier TJ, Alberti S, Di Francesco L, Marcantoni E, M\u00fcnch G, et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol. 2013;84(1):25\u201340.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"5126_CR157","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","volume":"76","author":"SH Barondes","year":"1994","unstructured":"Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994;76(4):597\u20138.","journal-title":"Cell"},{"key":"5126_CR158","doi-asserted-by":"publisher","first-page":"9247574","DOI":"10.1155\/2017\/9247574","volume":"2017","author":"L D\u00edaz-Alvarez","year":"2017","unstructured":"D\u00edaz-Alvarez L, Ortega E. The many roles of Galectin-3, a multifaceted molecule, in Innate Immune responses against pathogens. Mediators Inflamm. 2017;2017:9247574.","journal-title":"Mediators Inflamm"},{"key":"5126_CR159","doi-asserted-by":"crossref","unstructured":"Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP et al. Galectin-3: one molecule for an alphabet of diseases, from a to Z. Int J Mol Sci. 2018;19(2).","DOI":"10.3390\/ijms19020379"},{"issue":"14","key":"5126_CR160","first-page":"1146","volume":"135","author":"E Mammadova-Bach","year":"2020","unstructured":"Mammadova-Bach E, Gil-Pulido J, Sarukhanyan E, Burkard P, Shityakov S, Schonhart C, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3. Blood. 2020;135(14):1146\u201360.","journal-title":"Blood"},{"issue":"1","key":"5126_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0925-4439(03)00058-9","volume":"1638","author":"JW Goding","year":"2003","unstructured":"Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase\/phosphodiesterase family. Biochim Biophys Acta. 2003;1638(1):1\u201319.","journal-title":"Biochim Biophys Acta"},{"issue":"42","key":"5126_CR162","doi-asserted-by":"publisher","first-page":"39436","DOI":"10.1074\/jbc.M205623200","volume":"277","author":"A Tokumura","year":"2002","unstructured":"Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002;277(42):39436\u201342.","journal-title":"J Biol Chem"},{"issue":"1","key":"5126_CR163","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbior.2012.09.010","volume":"53","author":"J Hausmann","year":"2013","unstructured":"Hausmann J, Perrakis A, Moolenaar WH. Structure-function relationships of autotaxin, a secreted lysophospholipase D. Adv Biol Regul. 2013;53(1):112\u20137.","journal-title":"Adv Biol Regul"},{"issue":"9","key":"5126_CR164","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","volume":"1781","author":"J Aoki","year":"2008","unstructured":"Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008;1781(9):513\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"5126_CR165","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev.pharmtox.010909.105753","volume":"50","author":"JW Choi","year":"2010","unstructured":"Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157\u201386.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"5126_CR166","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12029-010-9186-4","volume":"42","author":"S Kazama","year":"2011","unstructured":"Kazama S, Kitayama J, Aoki J, Mori K, Nagawa H. Immunohistochemical detection of autotaxin (ATX)\/lysophospholipase D (lysoPLD) in submucosal invasive colorectal cancer. J Gastrointest Cancer. 2011;42(4):204\u201311.","journal-title":"J Gastrointest Cancer"},{"issue":"3","key":"5126_CR167","doi-asserted-by":"publisher","first-page":"e9741","DOI":"10.1371\/journal.pone.0009741","volume":"5","author":"M David","year":"2010","unstructured":"David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE. 2010;5(3):e9741.","journal-title":"PLoS ONE"},{"issue":"1","key":"5126_CR168","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12967-022-03603-4","volume":"20","author":"A Bolatai","year":"2022","unstructured":"Bolatai A, He Y, Wu N. Vascular endothelial growth factor and its receptors regulation in gestational diabetes mellitus and eclampsia. J Transl Med. 2022;20(1):400.","journal-title":"J Transl Med"},{"issue":"5","key":"5126_CR169","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/archsurg.1997.01430290087018","volume":"132","author":"Y Takahashi","year":"1997","unstructured":"Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg. 1997;132(5):541\u20136.","journal-title":"Arch Surg"},{"issue":"Suppl 1","key":"5126_CR170","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1634\/theoncologist.5-suppl_1-11","volume":"5","author":"LM Ellis","year":"2000","unstructured":"Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist. 2000;5(Suppl 1):11\u20135.","journal-title":"Oncologist"},{"issue":"16","key":"5126_CR171","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1038\/sj.onc.1208246","volume":"24","author":"F Fan","year":"2005","unstructured":"Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005;24(16):2647\u201353.","journal-title":"Oncogene"},{"issue":"6","key":"5126_CR172","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/bjc.2017.238","volume":"117","author":"R Bhattacharya","year":"2017","unstructured":"Bhattacharya R, Fan F, Wang R, Ye X, Xia L, Boulbes D, et al. Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion. Br J Cancer. 2017;117(6):848\u201355.","journal-title":"Br J Cancer"},{"issue":"1","key":"5126_CR173","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3892\/or.2016.5231","volume":"37","author":"M Zhao","year":"2017","unstructured":"Zhao M, Yu Z, Li Z, Tang J, Lai X, Liu L. Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: a potential self-regulating mechanism. Oncol Rep. 2017;37(1):601\u20137.","journal-title":"Oncol Rep"},{"issue":"1","key":"5126_CR174","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333.","journal-title":"Trends Mol Med"},{"issue":"3","key":"5126_CR175","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00665802","volume":"26","author":"L Seymour","year":"1993","unstructured":"Seymour L, Dajee D, Bezwoda WR. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat. 1993;26(3):247\u201352.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"5126_CR176","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.molonc.2015.05.009","volume":"9","author":"M Mazel","year":"2015","unstructured":"Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9(9):1773\u201382.","journal-title":"Mol Oncol"},{"issue":"3","key":"5126_CR177","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"5126_CR178","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052\u201362.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"5126_CR179","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1172\/JCI1509","volume":"101","author":"A Koenig","year":"1998","unstructured":"Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101(4):877\u201389.","journal-title":"J Clin Invest"},{"issue":"19 Pt 1","key":"5126_CR180","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","volume":"11","author":"JL Stevenson","year":"2005","unstructured":"Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins\u2013correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005;11(19 Pt 1):7003\u201311.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"5126_CR181","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1182\/blood-2013-08-520627","volume":"123","author":"A Kasirer-Friede","year":"2014","unstructured":"Kasirer-Friede A, Kang J, Kahner B, Ye F, Ginsberg MH, Shattil SJ. ADAP interactions with talin and kindlin promote platelet integrin \u03b1IIb\u03b23 activation and stable fibrinogen binding. Blood. 2014;123(20):3156\u201365.","journal-title":"Blood"},{"issue":"21","key":"5126_CR182","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1242\/jcs.205641","volume":"130","author":"J Gao","year":"2017","unstructured":"Gao J, Huang M, Lai J, Mao K, Sun P, Cao Z, et al. Kindlin supports platelet integrin \u03b1IIb\u03b23 activation by interacting with paxillin. J Cell Sci. 2017;130(21):3764\u201375.","journal-title":"J Cell Sci"},{"issue":"1","key":"5126_CR183","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/blood-2009-10-246751","volume":"117","author":"S Tadokoro","year":"2011","unstructured":"Tadokoro S, Nakazawa T, Kamae T, Kiyomizu K, Kashiwagi H, Honda S, et al. A potential role for \u03b1-actinin in inside-out \u03b1IIb\u03b23 signaling. Blood. 2011;117(1):250\u20138.","journal-title":"Blood"},{"issue":"2","key":"5126_CR184","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2174\/1389200217666151211121112","volume":"17","author":"A Giordano","year":"2016","unstructured":"Giordano A, Musumeci G, D\u2019Angelillo A, Rossini R, Zoccai GB, Messina S, et al. Effects of glycoprotein IIb\/IIIa antagonists: anti platelet aggregation and Beyond. Curr Drug Metab. 2016;17(2):194\u2013203.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"5126_CR185","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","volume":"33","author":"SL Goodman","year":"2012","unstructured":"Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci. 2012;33(7):405\u201312.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"5126_CR186","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/14728222.2012.669752","volume":"16","author":"M Das","year":"2012","unstructured":"Das M, Wakelee H. Targeting VEGF in lung cancer. Expert Opin Ther Targets. 2012;16(4):395\u2013406.","journal-title":"Expert Opin Ther Targets"},{"issue":"23","key":"5126_CR187","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus Irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u201342.","journal-title":"N Engl J Med"},{"issue":"7","key":"5126_CR188","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/bloodadvances.2022007863","volume":"7","author":"P Billiald","year":"2023","unstructured":"Billiald P, Slater A, Welin M, Clark JC, Loyau S, Pugni\u00e8re M, et al. Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition. Blood Adv. 2023;7(7):1258\u201368.","journal-title":"Blood Adv"},{"issue":"22","key":"5126_CR189","doi-asserted-by":"publisher","first-page":"8645","DOI":"10.1158\/0008-5472.CAN-09-1576","volume":"69","author":"OE Pardo","year":"2009","unstructured":"Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 2009;69(22):8645\u201351.","journal-title":"Cancer Res"},{"issue":"11","key":"5126_CR190","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.trecan.2017.09.004","volume":"3","author":"MGK Benesch","year":"2017","unstructured":"Benesch MGK, Yang Z, Tang X, Meng G, Brindley DN. Lysophosphatidate Signaling: the Tumor Microenvironment\u2019s New Nemesis. Trends Cancer. 2017;3(11):748\u201352.","journal-title":"Trends Cancer"},{"key":"5126_CR191","doi-asserted-by":"crossref","unstructured":"Jia Y, Li Y, Xu XD, Tian Y, Shang H. Design and development of Autotaxin inhibitors. Pharmaceuticals (Basel). 2021;14(11).","DOI":"10.3390\/ph14111203"},{"issue":"1","key":"5126_CR192","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1158\/1535-7163.MCT-19-0386","volume":"19","author":"X Tang","year":"2020","unstructured":"Tang X, Wuest M, Benesch MGK, Dufour J, Zhao Y, Curtis JM, et al. Inhibition of Autotaxin with GLPG1690 increases the efficacy of Radiotherapy and Chemotherapy in a mouse model of breast Cancer. Mol Cancer Ther. 2020;19(1):63\u201374.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"5126_CR193","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","volume":"6","author":"TM Maher","year":"2018","unstructured":"Maher TM, van der Aar EM, Van de Steen O, Allamassey L, Desrivot J, Dupont S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018;6(8):627\u201335.","journal-title":"Lancet Respir Med"},{"key":"5126_CR194","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijbiomac.2022.01.113","volume":"202","author":"X Zou","year":"2022","unstructured":"Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, et al. Targeting the PDGF\/PDGFR signaling pathway for cancer therapy: a review. Int J Biol Macromol. 2022;202:539\u201357.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"5126_CR195","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nm.4494","volume":"24","author":"P Roswall","year":"2018","unstructured":"Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, et al. Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nat Med. 2018;24(4):463\u201373.","journal-title":"Nat Med"},{"issue":"10","key":"5126_CR196","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1021\/bi5015425","volume":"54","author":"J Kuai","year":"2015","unstructured":"Kuai J, Mosyak L, Brooks J, Cain M, Carven GJ, Ogawa S, et al. Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-\u03b2. Biochemistry. 2015;54(10):1918\u201329.","journal-title":"Biochemistry"},{"key":"5126_CR197","doi-asserted-by":"publisher","first-page":"103374","DOI":"10.1016\/j.bioorg.2019.103374","volume":"94","author":"O Zarei","year":"2020","unstructured":"Zarei O, Sarri N, Dastmalchi S, Zokai F, Papadopoulos N, Lennartsson J, et al. Structure-based discovery of novel small molecule inhibitors of platelet-derived growth factor-B. Bioorg Chem. 2020;94:103374.","journal-title":"Bioorg Chem"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05126-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:59:46Z","timestamp":1731747586000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05126-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":197,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5126"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05126-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}